Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.
Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions.
复制标题
DOI：
10.3389/fimmu.2022.1018202
复制
发表时间：
2022
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
真菌感染在严重免疫功能障碍的患者中具有高死亡率。越来越多的证据表明，侵袭性真菌感染和癌症的免疫环境通过激活免疫检查点途径具有免疫细胞耗竭的共同特征。这一观察结果引发了几项临床前研究和临床病例报告，描述了阻断程序性细胞死亡蛋白1和细胞毒性T淋巴细胞抗原4免疫检查点途径作为治疗机会性真菌感染的辅助免疫增强策略。本综述的第一部分总结了检查点途径对真菌败血症、机会性霉菌感染和二型真菌感染的免疫病理学贡献的新证据。然后，我们回顾了免疫检查点抑制剂（ICI）作为抗真菌免疫疗法的潜在优点，包括对免疫保护作用和毒性机制的不完全了解。在这篇综述的第二部分，我们讨论了目前证据的局限性和ICIs作为抗真菌免疫增强策略的许多未知因素。基于这些知识的差距和从癌症免疫学研究中吸取的教训，我们概述了一个研究议程，以确定一个“甜蜜点”的ICI在医学真菌学。我们特别讨论了更细致入微的动物模型的重要性，需要研究ICI为基础的联合治疗，潜在的ICI耐药性，免疫微环境的作用，以及作为肿瘤治疗的一部分的ICI对各种病原真菌的自然免疫力的影响。
Opportunistic fungal infections have high mortality in patients with severe immune dysfunction. Growing evidence suggests that the immune environment of invasive fungal infections and cancers share common features of immune cell exhaustion through activation of immune checkpoint pathways. This observation gave rise to several preclinical studies and clinical case reports describing blockade of the Programmed Cell Death Protein 1 and Cytotoxic T-Lymphocyte Antigen 4 immune checkpoint pathways as an adjunct immune enhancement strategy to treat opportunistic fungal infections. The first part of this review summarizes the emerging evidence for contributions of checkpoint pathways to the immunopathology of fungal sepsis, opportunistic mold infections, and dimorphic fungal infections. We then review the potential merits of immune checkpoint inhibitors (ICIs) as an antifungal immunotherapy, including the incomplete knowledge of the mechanisms involved in both immuno-protective effects and toxicities. In the second part of this review, we discuss the limitations of the current evidence and the many unknowns about ICIs as an antifungal immune enhancement strategy. Based on these gaps of knowledge and lessons learned from cancer immunology studies, we outline a research agenda to determine a “sweet spot” for ICIs in medical mycology. We specifically discuss the importance of more nuanced animal models, the need to study ICI-based combination therapy, potential ICI resistance, the role of the immune microenvironment, and the impact of ICIs given as part of oncological therapies on the natural immunity to various pathogenic fungi.
登录
查看更多内容
影响因子：
3.1
作者：
Chau Tran Bao Vu;Thammahong, Arsa;Leelahavanichkul, Asada
通讯作者：
Leelahavanichkul, Asada
影响因子：
7.1
作者：
Cortegiani A;Misseri G;Fasciana T;Giammanco A;Giarratano A;Chowdhary A
通讯作者：
Chowdhary A
DOI：
10.1186/cc12711
发表时间：
2013-05-11
期刊：
Critical care (London, England)
影响因子：
--
作者：
Chang KC;Burnham CA;Compton SM;Rasche DP;Mazuski RJ;McDonough JS;Unsinger J;Korman AJ;Green JM;Hotchkiss RS
通讯作者：
Hotchkiss RS
影响因子：
20.3
作者：
Ben-Ami, Ronen;Lewis, Russell E.;Kontoyiannis, Dimitrios P.
通讯作者：
Kontoyiannis, Dimitrios P.
影响因子：
6.4
作者：
Baistrocchi, Shane R.;Lee, Mark J.;Sheppard, Donald C.
通讯作者：
Sheppard, Donald C.